Avere Merger Financing Grows to ~$820M With New $500M Placement
NXTC has more than doubled off its 52-week low of $1.55.
Summary
Financing commitments behind NextCure's reverse merger with Avere Therapeutics now total roughly $820M, split between a previously announced $320M private placement and a new $500M placement. About $266M of that is not cash at all — it comes from contributing and canceling Avere convertible notes. The SEC declared the merger Form S-4 effective November 6, so the registration hurdle is cleared. The remaining gate is the December 9, 2026 shareholder vote, where current NextCure holders are set to own only a sliver of the combined company. For a company this small, the size of the committed financing is the whole story — it determines whether the merged entity is funded past closing.
At the time of this announcement, NXTC was trading at $5.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.4M. The 52-week trading range was $1.55 to $15.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.